New high-cutoff dialyzer allows improved middle molecule clearance without an increase in albumin loss: A clinical crossover comparison in extended dialysis

Blood Purification

Volumn 34, Issue 3-4, 2013, Pages 246-252

  Schmidt, Julius J ^a   Hafer, Carsten ^a   Clajus, Christian ^a   Hadem, Johannes ^b   Beutel, Gernot ^c   Schmidt, Bernhard M W ^a   Kielstein, Jan T ^a  

^a Division of Nephrology and Hypertension   (Germany)

^b Hepatology and Endocrinology ^*  (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute kidney injury; Albumin loss; Extended dialysis; Middle molecules

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CREATININE; CYSTATIN C; POLYSULFONE; UREA;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ARTIFICIAL KIDNEY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIALYSATE; DIALYSIS; EXTENDED DIALYSIS; FEMALE; HUMAN; MALE; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ACUTE KIDNEY INJURY; ADULT; APACHE; BETA 2-MICROGLOBULIN; CREATININE; CROSS-OVER STUDIES; CYSTATIN C; FEMALE; HEMODIAFILTRATION; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; REFERENCE STANDARDS; SERUM ALBUMIN; UREA;

EID: 84869215762     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000342631     Document Type: Article

References (23)

1. Cohen G, Glorieux G, Thornalley P, Schepers E, Meert N, Jankowski J, Jankowski V, Argiles A, Anderstam B, Brunet P, Cerini C, Dou L, Deppisch R, Marescau B, Massy Z, Perna A, Raupachova J, Rodriguez M, Stegmayr B, Vanholder R, Horl WH: Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro-towards a standardized approach for research on uraemia. Nephrol Dial Transplant 2007; 22: 3381-3390. (Pubitemid 350212473)
2. Vanholder R, Meert N, Schepers E, Glorieux G, Argiles A, Brunet P, Cohen G, Drueke T, Mischak H, Spasovski G, Massy Z, Jankowski J: Review on uraemic solutes II-variability in reported concentrations: causes and consequences. Nephrol Dial Transplant 2007; 22: 3115-3121. (Pubitemid 350202539)
3. Faulhaber-Walter R, Hafer C, Jahr N, Vahlbruch J, Hoy L, Haller H, Fliser D, Kielstein JT: The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant 2009; 24: 2179-2186.
4. Jun M, Heerspink HJ, Ninomiya T, Gallagher M, Bellomo R, Myburgh J, Finfer S, Palevsky PM, Kellum JA, Perkovic V, Cass A: Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2010; 5: 956-963.
5. Cerda J, Ronco C: Modalities of continuous renal replacement therapy: technical and clinical considerations. Semin Dial 2009; 22: 114-122.
6. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645-654.
7. Tattersall J, Canaud B, Heimburger O, Pedrini L, Schneditz D, Van BW: High-flux or lowflux dialysis: a position statement following publication of the Membrane Permeability Outcome study. Nephrol Dial Transplant 2010; 25: 1230-1232.
8. Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr MJ, Haller H, Fliser D: Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis 2004; 43: 342-349. (Pubitemid 38146333)
9. Kumar VA, Craig M, Depner TA, Yeun JY: Extended daily dialysis: a new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis 2000; 36: 294-300. (Pubitemid 30485837)
10. Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK: Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int 2001; 60: 777-785. (Pubitemid 32678922)
11. Fliser D, Kielstein JT: Technology insight: treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol 2006; 2: 32-39. (Pubitemid 43355243)
12. Marshall MR, Creamer JM, Foster M, Ma TM, Mann SL, Fiaccadori E, Maggiore U, Richards B, Wilson VL, Williams AB, Rankin AP: Mortality rate comparison after switching from continuous to prolonged intermittent renal replacement for acute kidney injury in three intensive care units from different countries. Nephrol Dial Transplant, DOI: 10.1093/ndt/gfq694.
13. Ronco C, Brendolan A, Lupi A, Metry G, Levin NW: Effects of a reduced inner diameter of hollow fibers in hemodialyzers. Kidney Int 2000; 58: 809-817. (Pubitemid 30620031)
14. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Hattersley J, Evans ND, Chappell MJ, Cook M, Goehl H, Storr M, Bradwell AR: Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007; 18: 886-895. (Pubitemid 46434505)
15. Canaud B, Morena M, Cristol JP, Krieter D: Beta2-microglobulin, a uremic toxin with a double meaning. Kidney Int 2006; 69: 1297-1299.
16. Kielstein JT, Eugbers C, Bode-Boeger SM, Martens-Lobenhoffer J, Haller H, Joukhadar C, Traunmuller F, Knitsch W, Hafer C, Burkhardt O: Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacokinetic study. Nephrol Dial Transplant 2010; 25: 1537-1541.
17. Lee D, Haase M, Haase-Fielitz A, Paizis K, Goehl H, Bellomo R: A pilot, randomized, double-blind, cross-over study of high cutoff versus high-flux dialysis membranes. Blood Purif 2009; 28: 365-372.
18. Pellicano R, Polkinghorne KR, Kerr PG: Reduction in beta2-microglobulin with superflux versus high-flux dialysis membranes: results of a 6-week, randomized, doubleblind, crossover trial. Am J Kidney Dis 2008; 52: 93-101. (Pubitemid 351853258)
19. Krieter DH, Falkenhain S, Chalabi L, Collins G, Lemke HD, Canaud B: Clinical cross-over comparison of mid-dilution hemodiafiltration using a novel dialyzer concept and postdilution hemodiafiltration. Kidney Int 2005; 67: 349-356. (Pubitemid 40019258)
20. Krieter DH, Hackl A, Rodriguez A, Chenine L, Moragues HL, Lemke HD, Wanner C, Canaud B: Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. Nephrol Dial Transplant 2010; 25: 212-218.
21. De Smet RV, Dhondt A, Eloot S, Galli F, Waterloos MA, Vanholder R: Effect of the superflux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. Nephrol Dial Transplant 2007; 22: 2006-2012. (Pubitemid 47244774)
22. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G: Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol 2003; 14: 3251-3263. (Pubitemid 37509301)
23. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G: Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006; 17: 546-555.